Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Trial Details

NCT ID
NCT06196255
Phase
PHASE1 / PHASE2
Sponsor
Xuzhou Medical University
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • anti-FcRL5 CAR-T
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • The set subject inclusion criteria include multiple documents of multiple myeloma, no effective treatment options (e. g. autologous or allogeneic s…
  • Age is 18\~70 years old;
  • Expected survival period of\>12 weeks;
  • Multiple myeloma was diagnosed by physical examination, pathological examination, laboratory examination and imaging;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →